Body mass and atherogenic dyslipidemia as major determinants of blood levels of B-type natriuretic peptides in arab subjects with acute coronary syndromes

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 6, 2009, Pages 563-569

  Akanji, Abayomi O ^a   Suresh, Cheriyil G ^b   Al Radwan, Reem ^c   Fatania, Hasmukh R ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MUBARAK AL KABEER HOSPITAL   (Kuwait)

^c Central Blood Bank ^*  (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; TROPONIN I; UREA; URIC ACID;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARAB; ARTICLE; ATHEROGENESIS; BLOOD CELL COUNT; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOCRIT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST HIP RATIO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARABS; ATHEROSCLEROSIS; BODY MASS INDEX; CASE-CONTROL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; KUWAIT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RISK FACTORS;

EID: 73649139965     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0034     Document Type: Article

References (47)

1. Costello-Boerrigter LC, Burnett JC Jr. The prognostic value of N-terminal proB-type natriuretic peptide. Nat Clin Pract Cardiovasc Med 2005;2:194-201.
2. Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, Morrow DA, Drazner MH, McGuire DK, de Lemos JA. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 2005;96:1284-1289.
3. Sun T, Wang L, Zhang Y. Prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. Arch Med Res 2006;37:502-505.
4. Schnabel R, Lubos E, Rupprecht HJ, Espinola-Klein C, Bickel C, Lackner KJ, Cambien F, Tiret L, Munzel T, Blankenberg S. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006;47:552-558.
5. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 2005;112:110-116. (Pubitemid 40962576)
6. De Sutter J, De Bacquer D, Cuypers S, Delanghe J, De Buyzere M, Kornitzer M, De Backer G. Plasma N-terminal pro-brain natriuretic peptide concentration predicts coronary events in men at work: A report from the BELSTRESS study. Eur Heart J 2005;26:2644-2649.
7. Beer S, Golay S, Bardy D, Feihl F, Gaillard RC, Bachmann C, Waeber B, Ruiz J. Increased plasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in type 2 diabetic patients with vascular complications. Diabetes Metab 2005;31:567-573.
8. Dawson A, Jeyaseelan S, Morris AD, Struthers AD. B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus. Am J Cardiol 2005;96:933-934.
9. Igarashi M, Jimbu Y, Hirata A, Tominaga M. Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes. Endocr J 2005;52:353-362.
10. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, Edelman S, Henry R, Maisel A. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003;26:2081-2087.
11. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KA, Califf RM, Braunwald E; A to Z Investigators. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005;294:2866-2871.
12. Omland T. Clinical and laboratory diagnostics of cardiovascular disease: focus on natriuretic peptides and cardiac ischemia. Scand J Clin Lab Invest Suppl 2005;240:18-24.
13. Alwan AA. Cardiovascular diseases in the eastern Mediterranean region. World Hlth Stat Q 1993;46:97-100.
14. Antman E, Bassand J-P, Klein W, Ohman M, Sendon JLL, Ryden L, Simoons M, Tendera M. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: The Joint European Society of Cardiology/ American College of Cardiology Committee. J Am Coll Cardiol 2000;36:959-969.
15. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Levy D, Manolio T, Mendis S, Mensah G, Pajak A, Prineas RJ, Reddy KS, Roger VL, Rosamond WD, Shahar E, Sharrett AR, Sorlie P, Tunstall-Pedoe H. Case Definitions for Acute Coronary Heart Disease in Epidemiology and Clinical Research Studies: A Statement From the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003;108:2543-2549.
16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752. (Pubitemid 41532612)
17. Alberti KGMM, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome- a new worldwide definition. Lancet 2005;366:1059-1062. (Pubitemid 41338752)
18. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 972;18:499-502.
19. Al-Harbi K, Suresh CG, Zubaid M, Akanji AO. Establishing a gradient of risk in patients with acute coronary syndromes using troponin I measurements. Med Princ Pract 2002;11:18-22.
20. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Vogt W, Schomig A, Kastrati A. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 2005;95:553-557.
21. Takase H, Toriyama T, Sugiura T, Ueda R, Dohi Y. Brain natriuretic peptide in the prediction of recurrence of angina pectoris. Eur J Clin Invest 2004;34:79-84.
22. de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev Cardiovasc Med 2003;4(Suppl 4):S37-S46.
23. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-2918.
24. Cameron SJ, Green GB, White CN, Laterza OF, Clarke W, Kim H, Sokoll LJ. Assessment of BNP and NT-proBNP in emergency department patients presenting with suspected acute coronary syndromes. Clin Biochem 2006;39:11-18.
25. Struthers AD, Davies J. B-type natriuretic peptide: a simple new test to identify coronary artery disease? QJM 2005;98:765-769.
26. Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Nogueira MV, Campos A, Gamarski R, Masetto AC, Moutinho MA. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J 2005;26:234-240.
27. Palazzuoli A, Calabria P, Vecchiato L, Quatrini I, Carrera A, Bruni F, Puccetti L, Pastorelli M, Pasqui AL, Auteri A. Plasma brain natriuretic peptide levels in coronary heart disease with preserved systolic function. Clin Exp Med 2004;4:44-49.
28. Weber M, Dill T, Arnold R, Rau M, Ekinci O, Muller KD, Berkovitsch A, Mitrovic V, Hamm C. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004;148:612-620.
29. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004;6:327-333.
30. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-675. (Pubitemid 40239214)
31. Hong TC, Yeh HI, Shih BF, Wang AM, Chen CY, Hou CJ, Tsai CH. Brain natriuretic peptide and C-type natriuretic peptide are differently regulated by age but similarly elevated in coronary artery disease. Acta Cardiol 2006;61:1-5.
32. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Maisel AS. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J 2006;151:999-1005.
33. St Peter JV, Hartley GG, Murakami MM, Apple FS.B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: Relationship to body mass index and gastric bypass surgery. Clin Chem 2006;52:680-685.
34. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH Jr, de Lemos JA. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163-2168.
35. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005;149:744-750.
36. McCord J, Mundy BJ, Hudson MP, Maisel AS, Hollander JE, Abraham WT, Steg PG, Omland T, Knudsen CW, Sandberg KR, McCullough PA; Breathing Not Properly Multinational Study Investigators. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004;164:2247-2252.
37. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-1595.
38. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600.
39. Dessi-Fulgheri P, Sarzani R, Rappelli A. Role of the natriuretic peptide system in lipogenesis/ lipolysis. Nutr Metab Cardiovasc Dis 2003;13:244-249.
40. Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, Goldberg IJ. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specifi c lipoprotein lipase transgenic mouse. J Biol Chem 2004;279:4204-4211.
41. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003;5:599-606
42. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-982.
43. Palumbo B, Siepi D, Lupattelli G, Sinzinger H, Fiorucci G, Anniboletti PF, Latini RA, Mannarino E, Palumbo R. Usefulness of brain natriuretic peptide levels to discriminate patients with stable angina pectoris without and with electrocardiographic myocardial ischemia and patients with healed myocardial infarction. Am J Cardiol 2004;94:780-783.
44. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-1272.
45. Wold Knudsen C, Vik-Mo H, Omland T. Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP). Clin Sci (Lond) 2005;109:69-74.
46. Zubaid M, Suresh CG, Thalib L, Rashed W. Differential distribution of risk factors and outcome of acute coronary syndrome in Kuwait: Three years' experience. Med Princ Pract 2004;13:63-68.
47. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007;115:1345-1353.